Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00000706
Status:
COMPLETED
Last Update Posted:
2021-11-03
First Post:
1999-11-02
Brief Title:
Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine
Status:
COMPLETED
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Part I studies the effect of quinine on how zidovudine AZT is used by the body and eliminated through the kidneys in HIV infected patients Part II studies the effect of probenecid and quinine on the same aspects
Because AZT leaves the bloodstream quickly patients must take the drug frequently to keep adequate amounts in their bodies Probenecid and quinine may slow down the rate at which AZT leaves the body Therefore taking these drugs along with AZT may reduce the amount of AZT needed for treatment
Because AZT leaves the bloodstream quickly patients must take the drug frequently to keep adequate amounts in their bodies Probenecid and quinine may slow down the rate at which AZT leaves the body Therefore taking these drugs along with AZT may reduce the amount of AZT needed for treatment
Detailed Description:
Because AZT leaves the bloodstream quickly patients must take the drug frequently to keep adequate amounts in their bodies Probenecid and quinine may slow down the rate at which AZT leaves the body Therefore taking these drugs along with AZT may reduce the amount of AZT needed for treatment
In part I four patients who are now receiving AZT at the usual dose take part in pharmacokinetic studies how much of the drug enters the blood stream what happens to the drug in the body and how it leaves the body of AZT defined after a dose while at steady state and then again after a new steady state has been reached following the addition of quinine sulfate Part II studies the pharmacokinetics of AZT in eight patients receiving AZT at 1 of 2 doses and then at the lower dose of AZT plus probenecid with or without quinine
In part I four patients who are now receiving AZT at the usual dose take part in pharmacokinetic studies how much of the drug enters the blood stream what happens to the drug in the body and how it leaves the body of AZT defined after a dose while at steady state and then again after a new steady state has been reached following the addition of quinine sulfate Part II studies the pharmacokinetics of AZT in eight patients receiving AZT at 1 of 2 doses and then at the lower dose of AZT plus probenecid with or without quinine
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 11003 | REGISTRY | DAIDS ES Registry Number | None |